摘要
目的分析腮腺恶性肿瘤患者肿瘤组织凋亡抑制因子(Survivin)的表达水平及其与腮腺肿瘤临床病理特征之间的相关性。方法采用回顾性研究,收集深圳市龙华区中心医院35例正常腮腺腺体组织(正常对照组)、56例腮腺良性肿瘤组织(良性对照组)及95例腮腺恶性肿瘤组织(恶性肿瘤组),通过免疫组化染色法对三组石蜡标本中Survivin的表达水平进行检测,并进一步分析Survivin阳性表达与腮腺恶性肿瘤患者临床病理特征的相关性。结果相比正常对照组[0/35(0%)],良性对照组[12/56(21. 43%)]、恶性肿瘤组[63/95(66. 32%)]Survivin阳性表达率均升高(P <0. 05);与良性对照组相比,恶性肿瘤组Survivin阳性表达率显著升高(P <0. 05)。不同性别、年龄及是否伴有淋巴结转移的患者Survivin表达水平的比较,并无显著差异(P> 0. 05);不同肿瘤直径、TNM分期及肿瘤生物学行为Survivin表达水平的比较,存在显著差异(P <0. 01)。结论 Survivin过表达于腮腺恶性肿瘤组织,且可促进肿瘤形成和进展,Survivin有望成为临床诊断、治疗和评估腮腺恶性肿瘤预后状况的重要肿瘤标志物,可能是肿瘤基因靶向治疗的潜在靶点。
Objective To analyze the expression of Survivin in parotid malignant tumors and its correlation with clinicopathological features of parotid tumors. Methods A retrospective study was conducted to collect 35 normal parotid gland tissues( normal control group),56 benign parotid tumors( benign control group) and 95 malignant parotid tumors( malignant tumor group). The expression of Survivin in three groups of paraffin specimens was detected by immunohistochemical staining,and the positive expression of Survivin and malignant parotid tumors were further analyzed. The correlation of clinicopathological features in patients with tumors. Results Compared with normal control group [0/35( 0%)],the positive expression rate of Survivin in benign control group [12/56( 21. 43%)]and malignant tumor group [63/95( 66. 32%)]was significantly higher( P < 0. 05). Compared with the benign control group,the positive expression rate of Survivin was significantly increased in the malignant tumor group( P < 0. 05). There was no significant difference in Survivin expression among patients with different sex,age and lymph node metastasis( P > 0. 05);there was significant difference in Survivin expression among different tumor diameters,TNM stages and biological behavior( P < 0. 01). Conclusion Survivin is overexpressed in parotid malignant tumors and can promote tumorigenesis and progression.It is expected to become an important tumor marker for clinical diagnosis,treatment and evaluation of prognosis of parotid malignant tumors,and may be a potential target for gene targeting therapy of parotid malignant tumors.
作者
雷欣
许晓虎
黄莹
LEI Xin;XU Xiao-hu;HUANG Ying(Department of Stomatology,Central Hospital of Longhua District of Shenzhen,Shenzhen Guangdong 518110,China.)
出处
《临床和实验医学杂志》
2019年第17期1848-1851,共4页
Journal of Clinical and Experimental Medicine
基金
深圳市科技研发基础研究项目(编号:JCYJ20160428142231354)
关键词
腮腺肿瘤
凋亡抑制因子
免疫组化法
临床病理特征
Parotid gland neoplasms
Inhibitor of apoptosis
Immunohistochemistry
Clinicopathological feature
